Simulations Plus Enters New Funded Collaboration to Enhance Top-Rated GastroPlus® ACAT™ Model for Oral Absorption of Pepti...
January 05 2021 - 8:30AM
Business Wire
New modeling approaches will accelerate the
evaluation of innovative formulation strategies
Simulations Plus, Inc. (Nasdaq: SLP), a leading
provider of modeling and simulation solutions for the
pharmaceutical, biotechnology, chemical, and consumer goods
industries, today announced that it has entered into a new funded
collaboration with a large pharmaceutical company to add novel
mechanisms for oral peptide formulations within the top-rated
GastroPlus® Advanced Compartmental Absorption and Transit (ACAT™)
mechanistic model.
“Our partner, a frequent user of the GastroPlus platform across
multiple research sites worldwide, has a growing portion of their
development pipeline focused on therapeutic peptides and proteins,”
said Dr. Viera Lukacova, chief scientist at Simulations Plus. “Part
of their strategy involves designing oral delivery systems which
can safely and efficiently complement the traditional invasive
routes for these biomolecules. In this new collaborative effort, we
will expand the applicability of GastroPlus to simulate intestinal
absorption of larger molecules and the effect of permeation
enhancers within oral formulations. The novel approaches and
workflows will be validated through unique data provided to us by
our partner, with the results serving as the foundational elements
for peer-reviewed journal manuscripts describing the exciting
improvements.”
“What a great way to kick off 2021,” added John DiBella,
Lancaster division president for Simulations Plus. “Over the past
several years, we have driven advances in modeling and simulation
science for injectable formulations of both small and large
molecules. With the market for oral delivery of therapeutic
peptides and proteins expected to increase significantly over the
next several years, it was important for us to partner with experts
and embrace a leadership role to expand oral absorption modeling
beyond small molecules. Like other funded collaborations, we will
own all improvements made to our software programs, and our entire
user community can access these new capabilities to accelerate
research timelines and develop better medicines for the patients we
all serve. We continue to welcome and invite future collaborations
across our entire suite of software programs.”
About Simulations Plus, Inc.
Simulations Plus, Inc., is a leading provider of modeling and
simulation software and consulting services supporting drug
discovery, development research, and regulatory submissions. With
our subsidiaries, Cognigen, DILIsym Services, and Lixoft, we offer
solutions which bridge machine learning, physiologically based
pharmacokinetics, quantitative systems pharmacology/toxicology, and
population PK/PD modeling approaches. Our technology is licensed
and applied by major pharmaceutical, biotechnology, chemical,
consumer goods companies and regulatory agencies worldwide. For
more information, visit our website at
www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation
Reform Act of 1995 – With the exception of historical
information, the matters discussed in this press release are
forward-looking statements that involve a number of risks and
uncertainties. Words like “believe,” “expect” and “anticipate” mean
that these are our best estimates as of this writing, but that
there can be no assurances that expected or anticipated results or
events will actually take place, so our actual future results could
differ significantly from those statements. Factors that could
cause or contribute to such differences include, but are not
limited to: our ability to maintain our competitive advantages,
acceptance of new software and improved versions of our existing
software by our customers, the general economics of the
pharmaceutical industry, our ability to finance growth, our ability
to continue to attract and retain highly qualified technical staff,
our ability to identify and close acquisitions on terms favorable
to the Company, and a sustainable market. Further information on
our risk factors is contained in our quarterly and annual reports
and filed with the U.S. Securities and Exchange Commission.
Follow us on Twitter | LinkedIn
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210105005260/en/
Simulations Plus Investor Relations
Ms. Renee Bouche 661-723-7723 renee@simulations-plus.com
Hayden IR Mr. Cameron Donahue
651-653-1854 slp@haydenir.com
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Sep 2023 to Sep 2024